Stockreport

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer

BAVARIAN NORDIC R/I S/ADR  (BVNRY) 
NASDAQ:AMEX Investor Relations: bavarian-nordic.com/investor.aspx
PDF Bavarian Nordic-sponsored study has commenced dosingStudy marks the second of three planned Phase 2 combination studies of CV301 with checkpoint inhibitors in solid tumo [Read more]